Pages that link to "Q84057525"
Jump to navigation
Jump to search
The following pages link to Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo (Q84057525):
Displaying 6 items.
- A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors (Q37076922) (← links)
- A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications (Q38149466) (← links)
- Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3). (Q38866773) (← links)
- The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting (Q44549744) (← links)
- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics (Q47570404) (← links)
- TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas' heart disease (Q92311732) (← links)